Huntington’s disease: from huntingtin function and dysfunction to therapeutic strategies

被引:0
|
作者
M. Borrell-Pagès
D. Zala
S. Humbert
F. Saudou
机构
[1] Institut Curie,CNRS UMR 146
[2] Universitat Autonoma de Barcelona,Neurovascular Research Laboratory, Vall d’Hebron Hospital
关键词
CAG expansion; polyglutamine; aggregation; intracellular transport; transcription; signal transduction; therapy;
D O I
暂无
中图分类号
学科分类号
摘要
Huntington’s disease (HD) is a neurodegenerative disorder that usually starts in middle age and is characterized by involuntary movements (chorea), personality changes and dementia, leading to death within 10–20 years. The defective gene in HD contains a trinucleotide CAG repeat expansion within its coding region that expresses a polyglutamine repeat in the protein huntingtin. Together with the characteristic formation of aggregates in HD, aberrant protein interactions and several post-translational modifications affect huntingtin during disease progression and lead to the dysfunction and death of selective neurons in the brains of patients. The exact molecular mechanisms by which mutant huntingtin induces cell death are not completely understood but may involve the gain of new toxic functions and the loss of the beneficial properties of huntingtin. This review focuses on the cellular functions in which huntingtin is involved and how a better understanding of pathogenic pathways can lead to new therapeutic approaches.
引用
收藏
页码:2642 / 2660
页数:18
相关论文
共 50 条
  • [1] Huntington's disease:: from huntingtin function and dysfunction to therapeutic strategies
    Borrell-Pages, M.
    Zala, D.
    Humbert, S.
    Saudou, F.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2006, 63 (22) : 2642 - 2660
  • [2] Huntington's Disease: Function and Dysfunction of Huntingtin in Axonal Transport
    Saudou, Frederic
    Humbert, Sandrine
    INTRACELLULAR TRAFFIC AND NEURODEGENERATIVE DISORDERS, 2009, : 115 - +
  • [3] Normal huntingtin function in Huntington's disease
    Cattaneo, E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 13 - 13
  • [4] Huntingtin-lowering strategies for Huntington's disease
    Barker, Roger A.
    Fujimaki, Motoki
    Rogers, Priya
    Rubinsztein, David C.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (10) : 1125 - 1132
  • [5] Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease
    Tabrizi, Sarah J.
    Ghosh, Rhia
    Leavitt, Blair R.
    NEURON, 2019, 101 (05) : 801 - 819
  • [6] Dysfunction of wild-type huntingtin in Huntington's Disease
    Cattaneo, E
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2002, 10 : 60 - 60
  • [7] Therapeutic strategies in Huntington's disease
    Alberch, J
    Canals, JM
    Pérez-Navarro, E
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2003, 13 (04) : 449 - 465
  • [8] Therapeutic strategies for Huntington's disease
    Estevez-Fraga, Carlos
    Flower, Michael D.
    Tabrizi, Sarah J.
    CURRENT OPINION IN NEUROLOGY, 2020, 33 (04) : 508 - 518
  • [9] Cognitive dysfunction in Huntington's disease: mechanisms and therapeutic strategies beyond BDNF
    Puigdellivol, Mar
    Saavedra, Ana
    Perez-Navarro, Esther
    BRAIN PATHOLOGY, 2016, 26 (06) : 752 - 771
  • [10] Normal huntingtin function: An alternative approach to Huntington's disease
    Cattaneo, E
    Zuccato, C
    Tartari, M
    NATURE REVIEWS NEUROSCIENCE, 2005, 6 (12) : 919 - 930